In healthy individuals, CA-125 is present in low amounts, but certain types of ovarian cancer, particularly epithelial ovarian cancer, can cause this protein to be overproduced and released into the blood. Conversely, some early-stage ovarian cancers may not produce enough CA-125 to trigger a positive result, making it a tool best used in conjunction with other diagnostic methods rather than as a standalone screening test for the general population.
Ovarian Cancer Biomarkers New Research: Advancing Detection with HE4 and ROMA
This signal prompts a visit to the doctor, where the initial focus often shifts to blood work and imaging. Understanding ovarian cancer lab tests is a critical step in navigating a complex medical landscape.
HE4 is a protein that is often elevated in ovarian cancer but is less likely to be raised by benign conditions. However, it is crucial to understand that an elevated CA-125 level is not synonymous with cancer.
New Ovarian Cancer Biomarkers Research: HE4 and the ROMA Index
These advancements aim to catch the disease earlier and provide a clearer picture of the cancer's aggressiveness. HE4 and the ROMA Index: Advancing Detection To address the limitations of CA-125 alone, the medical community has incorporated Human Epididymis Protein 4 (HE4) into the diagnostic toolkit.
More About Ovarian cancer lab tests
Looking at Ovarian cancer lab tests from another angle can help expand the discussion and give readers a second clear paragraph under the same section.
More perspective on Ovarian cancer lab tests can make the topic easier to follow by connecting earlier points with a few simple takeaways.
